| Market Capitalization (Millions $) |
643 |
| Shares
Outstanding (Millions) |
545 |
| Employees |
14 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Xtl Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd is a publicly traded biopharmaceutical company based in Israel. It was founded in 1993 and focuses on the development of drugs to treat viral infections, autoimmune diseases, and cancer.
The company's flagship product is called hCDR1 (Edratide), which is a novel immunomodulatory drug designed to treat systemic lupus erythematosus (SLE) and other autoimmune diseases. The drug has completed two Phase II clinical trials and has shown promising results in reducing disease activity and improving patient quality of life.
XTL's other main product is called rHuEPO, which is a recombinant human erythropoietin used to treat anemia in patients with chronic renal failure. The drug has completed Phase II clinical trials and is in the process of being licensed.
In addition to these two products, XTL is also working on the development of drugs for the treatment of hepatitis C, HIV/AIDS, and solid tumor cancers. The company's drug development process involves identifying new targets, conducting pre-clinical studies, and testing the drugs in clinical trials.
The company has a strong intellectual property portfolio, with over 120 patents and patent applications both in the US and internationally. It has also entered into partnerships with other biotech and pharmaceutical companies, including Spanish drug maker Ferrer International, to develop and commercialize its products.
XTL has a highly experienced management team, including CEO Joshua Levine, who has over 30 years of experience in the biotech industry. The company is publicly traded on the Tel Aviv Stock Exchange (TASE) and on the NASDAQ under the ticker symbol XTLB.
Overall, XTL Biopharmaceuticals Ltd is a promising biotech company that has made significant strides in the development of novel drugs for the treatment of autoimmune diseases, viral infections, and cancer. Despite the challenges of drug development, the company has maintained a strong focus on innovation and is dedicated to improving the lives of patients around the world.
Company Address: 26 Ben-Gurion St Ramat Gan 5112001
Company Phone Number: 3-6116600 Stock Exchange / Ticker: NASDAQ XTLB
|
0.09% 